In the 2021 revised World Health Organization Classification of Central Nervous System Tumours (WHO CNS5) classification, isocitrate dehydrogenase 1/2 -wild-type (IDHwt) gliomas lacking necrosis and/or vascular proliferations, but with a TERT-promotor (TERTp) mutation, and/or EGFR amplification, and/or combined gain of chromosome 7 and loss of chromosome 10 (7+/10−), are now classified as IDHwt glioblastoma.1 These formerly labeled “diffuse astrocytomas, IDH wild-type, with genetic features of glioblastoma” are not separated anymore from histologically defined glioblastomas. The gene discussed is TERT; the disease is glioblastoma.